This is a preview of subscription content, log in via an institution to check access.
Notes
The study was partly funded by Sividon Diagnostics GmbH, Germany.
Reference
Blank PR, et al. Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. PharmacoEconomics : 18 Nov 2014. Available from: URL: http://doi.org/10.1007/s40273-014-0227-x
Rights and permissions
About this article
Cite this article
Molecular testing in breast cancer: better outcomes, lower costs. PharmacoEcon Outcomes News 717, 27 (2014). https://doi.org/10.1007/s40274-014-1752-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1752-8